| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 99 | 2025 | 954 | 15.190 |
Why?
|
| Oxidative Stress | 81 | 2022 | 619 | 10.380 |
Why?
|
| Endothelium, Vascular | 45 | 2024 | 305 | 7.930 |
Why?
|
| Cognitive Dysfunction | 28 | 2025 | 268 | 5.240 |
Why?
|
| Endothelial Cells | 35 | 2025 | 333 | 5.000 |
Why?
|
| NF-E2-Related Factor 2 | 17 | 2024 | 118 | 4.700 |
Why?
|
| Neurovascular Coupling | 24 | 2024 | 152 | 4.530 |
Why?
|
| Stilbenes | 22 | 2016 | 90 | 4.470 |
Why?
|
| Animals | 172 | 2025 | 9954 | 3.990 |
Why?
|
| Cellular Senescence | 15 | 2024 | 121 | 3.870 |
Why?
|
| Insulin-Like Growth Factor I | 19 | 2019 | 290 | 3.620 |
Why?
|
| Reactive Oxygen Species | 33 | 2019 | 277 | 3.550 |
Why?
|
| Antioxidants | 23 | 2019 | 222 | 3.530 |
Why?
|
| Mitochondria | 21 | 2020 | 325 | 3.280 |
Why?
|
| Coronary Vessels | 18 | 2012 | 151 | 3.230 |
Why?
|
| Hypertension | 19 | 2023 | 304 | 3.160 |
Why?
|
| Longevity | 22 | 2022 | 129 | 3.110 |
Why?
|
| Mice | 79 | 2024 | 4402 | 2.690 |
Why?
|
| Vascular Diseases | 9 | 2019 | 67 | 2.680 |
Why?
|
| Brain | 32 | 2024 | 697 | 2.620 |
Why?
|
| Hippocampus | 15 | 2021 | 186 | 2.550 |
Why?
|
| Alzheimer Disease | 12 | 2023 | 208 | 2.520 |
Why?
|
| Inflammation | 26 | 2023 | 598 | 2.400 |
Why?
|
| Cerebrovascular Circulation | 26 | 2025 | 220 | 2.350 |
Why?
|
| Mice, Inbred C57BL | 51 | 2024 | 1474 | 2.280 |
Why?
|
| Blood Vessels | 6 | 2020 | 58 | 2.270 |
Why?
|
| Neovascularization, Physiologic | 12 | 2019 | 123 | 2.020 |
Why?
|
| Obesity | 11 | 2024 | 647 | 1.990 |
Why?
|
| Cardiovascular Diseases | 9 | 2018 | 346 | 1.970 |
Why?
|
| Cognition | 15 | 2024 | 294 | 1.910 |
Why?
|
| NF-kappa B | 17 | 2017 | 187 | 1.910 |
Why?
|
| Male | 102 | 2024 | 12866 | 1.900 |
Why?
|
| Disease Models, Animal | 39 | 2023 | 1394 | 1.890 |
Why?
|
| Rats | 43 | 2018 | 1536 | 1.810 |
Why?
|
| Vasodilation | 18 | 2019 | 114 | 1.670 |
Why?
|
| Microvessels | 15 | 2021 | 85 | 1.670 |
Why?
|
| Carotid Arteries | 8 | 2011 | 52 | 1.670 |
Why?
|
| Hydrogen Peroxide | 19 | 2019 | 138 | 1.640 |
Why?
|
| Caloric Restriction | 10 | 2024 | 73 | 1.610 |
Why?
|
| Microcirculation | 15 | 2020 | 111 | 1.570 |
Why?
|
| Cells, Cultured | 31 | 2017 | 969 | 1.550 |
Why?
|
| Aorta | 10 | 2019 | 123 | 1.540 |
Why?
|
| Humans | 107 | 2025 | 26856 | 1.530 |
Why?
|
| Cerebral Hemorrhage | 10 | 2023 | 90 | 1.530 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2013 | 244 | 1.520 |
Why?
|
| Apoptosis | 26 | 2018 | 737 | 1.510 |
Why?
|
| Cognition Disorders | 9 | 2017 | 181 | 1.490 |
Why?
|
| Growth Hormone | 8 | 2022 | 103 | 1.460 |
Why?
|
| Blood-Brain Barrier | 10 | 2021 | 82 | 1.400 |
Why?
|
| Cerebrovascular Disorders | 4 | 2018 | 46 | 1.380 |
Why?
|
| Inflammation Mediators | 9 | 2018 | 152 | 1.340 |
Why?
|
| Peripheral Arterial Disease | 8 | 2022 | 113 | 1.320 |
Why?
|
| Astrocytes | 7 | 2023 | 73 | 1.240 |
Why?
|
| Bone Morphogenetic Proteins | 6 | 2011 | 32 | 1.230 |
Why?
|
| MicroRNAs | 4 | 2019 | 278 | 1.210 |
Why?
|
| Transcriptome | 4 | 2024 | 198 | 1.200 |
Why?
|
| Muscle, Smooth, Vascular | 12 | 2018 | 77 | 1.190 |
Why?
|
| Age Factors | 18 | 2024 | 716 | 1.150 |
Why?
|
| Gene Expression Regulation | 13 | 2024 | 624 | 1.120 |
Why?
|
| White Matter | 3 | 2023 | 89 | 1.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2012 | 72 | 1.080 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2015 | 38 | 1.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 321 | 1.000 |
Why?
|
| DNA Damage | 6 | 2019 | 147 | 0.990 |
Why?
|
| Diet, High-Fat | 8 | 2024 | 130 | 0.980 |
Why?
|
| Gait | 7 | 2021 | 58 | 0.970 |
Why?
|
| Rats, Inbred F344 | 14 | 2019 | 167 | 0.950 |
Why?
|
| RNA, Messenger | 13 | 2016 | 645 | 0.950 |
Why?
|
| Pulmonary Artery | 3 | 2009 | 68 | 0.940 |
Why?
|
| Phenotype | 14 | 2021 | 664 | 0.940 |
Why?
|
| Signal Transduction | 12 | 2019 | 1339 | 0.900 |
Why?
|
| Arteries | 3 | 2018 | 65 | 0.900 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 18 | 0.900 |
Why?
|
| Amyloid beta-Peptides | 3 | 2020 | 46 | 0.900 |
Why?
|
| Biomarkers | 15 | 2024 | 731 | 0.890 |
Why?
|
| Cerebral Arteries | 4 | 2019 | 33 | 0.890 |
Why?
|
| Aged | 31 | 2024 | 5169 | 0.880 |
Why?
|
| Pandemics | 3 | 2023 | 166 | 0.850 |
Why?
|
| Hyperglycemia | 4 | 2011 | 77 | 0.830 |
Why?
|
| NADPH Oxidases | 13 | 2013 | 68 | 0.810 |
Why?
|
| Dementia, Vascular | 8 | 2025 | 60 | 0.810 |
Why?
|
| Sirtuins | 4 | 2009 | 16 | 0.790 |
Why?
|
| Vascular Stiffness | 2 | 2019 | 41 | 0.790 |
Why?
|
| Catalase | 3 | 2019 | 48 | 0.780 |
Why?
|
| Neuronal Plasticity | 2 | 2019 | 49 | 0.780 |
Why?
|
| Zoonoses | 2 | 2021 | 13 | 0.760 |
Why?
|
| Cognitive Aging | 3 | 2020 | 21 | 0.750 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 40 | 0.740 |
Why?
|
| Superoxides | 9 | 2010 | 60 | 0.730 |
Why?
|
| Mice, Knockout | 15 | 2018 | 781 | 0.730 |
Why?
|
| Microvascular Rarefaction | 2 | 2021 | 13 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 144 | 0.720 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 6 | 0.710 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.680 |
Why?
|
| Hyperemia | 4 | 2022 | 31 | 0.660 |
Why?
|
| NAD | 2 | 2019 | 81 | 0.660 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 47 | 0.660 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 51 | 0.660 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2019 | 3 | 0.660 |
Why?
|
| Nicotinamide Mononucleotide | 4 | 2020 | 23 | 0.650 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2019 | 15 | 0.650 |
Why?
|
| Eicosanoids | 1 | 2019 | 10 | 0.640 |
Why?
|
| Transcription, Genetic | 9 | 2016 | 399 | 0.640 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 48 | 0.630 |
Why?
|
| Gene Expression Profiling | 6 | 2024 | 437 | 0.600 |
Why?
|
| Cytokines | 10 | 2019 | 437 | 0.600 |
Why?
|
| Down-Regulation | 5 | 2016 | 196 | 0.600 |
Why?
|
| Hemodynamics | 5 | 2021 | 220 | 0.590 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2020 | 109 | 0.580 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 8 | 0.580 |
Why?
|
| Fibroblasts | 3 | 2017 | 150 | 0.580 |
Why?
|
| Sirtuin 1 | 6 | 2020 | 39 | 0.580 |
Why?
|
| Angiotensin II | 9 | 2021 | 54 | 0.570 |
Why?
|
| Nitric Oxide | 13 | 2019 | 151 | 0.570 |
Why?
|
| Transforming Growth Factor beta | 4 | 2008 | 77 | 0.560 |
Why?
|
| Neocortex | 1 | 2016 | 7 | 0.540 |
Why?
|
| Bone Morphogenetic Protein 4 | 4 | 2009 | 14 | 0.540 |
Why?
|
| Gene Expression | 7 | 2018 | 405 | 0.540 |
Why?
|
| Enzyme Inhibitors | 12 | 2019 | 247 | 0.530 |
Why?
|
| Energy Metabolism | 3 | 2019 | 176 | 0.520 |
Why?
|
| Female | 34 | 2024 | 14462 | 0.520 |
Why?
|
| Vasodilator Agents | 10 | 2013 | 79 | 0.520 |
Why?
|
| Arterioles | 8 | 2022 | 60 | 0.520 |
Why?
|
| Bone Morphogenetic Protein 2 | 4 | 2009 | 29 | 0.510 |
Why?
|
| Smoking | 3 | 2009 | 466 | 0.510 |
Why?
|
| Rats, Wistar | 15 | 2015 | 145 | 0.510 |
Why?
|
| Cerebral Cortex | 6 | 2021 | 133 | 0.500 |
Why?
|
| Nitric Oxide Synthase Type III | 7 | 2016 | 54 | 0.500 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2011 | 588 | 0.500 |
Why?
|
| Mercenaria | 2 | 2013 | 6 | 0.490 |
Why?
|
| Cell Adhesion | 8 | 2014 | 133 | 0.490 |
Why?
|
| Geriatrics | 3 | 2020 | 41 | 0.480 |
Why?
|
| tert-Butylhydroperoxide | 2 | 2012 | 7 | 0.480 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 6 | 2011 | 40 | 0.470 |
Why?
|
| Adaptation, Physiological | 3 | 2015 | 158 | 0.470 |
Why?
|
| Liver | 4 | 2016 | 415 | 0.460 |
Why?
|
| Dwarfism | 4 | 2014 | 27 | 0.450 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2024 | 72 | 0.450 |
Why?
|
| Maze Learning | 8 | 2019 | 78 | 0.440 |
Why?
|
| Middle Cerebral Artery | 6 | 2021 | 48 | 0.440 |
Why?
|
| Acetylcholine | 9 | 2010 | 73 | 0.430 |
Why?
|
| Primates | 2 | 2014 | 22 | 0.420 |
Why?
|
| Ribonuclease III | 1 | 2012 | 6 | 0.420 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 26 | 0.410 |
Why?
|
| Rats, Inbred BN | 6 | 2019 | 70 | 0.410 |
Why?
|
| Tissue Culture Techniques | 5 | 2015 | 30 | 0.390 |
Why?
|
| Intercellular Adhesion Molecule-1 | 8 | 2012 | 57 | 0.390 |
Why?
|
| Cell Proliferation | 8 | 2019 | 770 | 0.390 |
Why?
|
| Homeostasis | 6 | 2016 | 113 | 0.380 |
Why?
|
| Rejuvenation | 3 | 2020 | 26 | 0.380 |
Why?
|
| Oxygen | 6 | 2020 | 218 | 0.380 |
Why?
|
| Mole Rats | 3 | 2008 | 6 | 0.380 |
Why?
|
| Glutamate-Cysteine Ligase | 4 | 2011 | 25 | 0.370 |
Why?
|
| Parabiosis | 2 | 2022 | 17 | 0.370 |
Why?
|
| Free Radicals | 1 | 2011 | 39 | 0.370 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2011 | 94 | 0.360 |
Why?
|
| Blood Pressure | 9 | 2015 | 351 | 0.360 |
Why?
|
| Blotting, Western | 12 | 2010 | 503 | 0.350 |
Why?
|
| Up-Regulation | 7 | 2013 | 239 | 0.350 |
Why?
|
| Dementia | 3 | 2023 | 87 | 0.340 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 487 | 0.340 |
Why?
|
| NG-Nitroarginine Methyl Ester | 6 | 2019 | 31 | 0.340 |
Why?
|
| Platelet Aggregation | 3 | 2007 | 43 | 0.340 |
Why?
|
| Mice, Inbred ICR | 3 | 2018 | 26 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 323 | 0.330 |
Why?
|
| Reactive Nitrogen Species | 2 | 2009 | 10 | 0.330 |
Why?
|
| Glucose | 5 | 2011 | 190 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 121 | 0.330 |
Why?
|
| Macaca mulatta | 4 | 2016 | 47 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2014 | 176 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type II | 6 | 2009 | 38 | 0.320 |
Why?
|
| Hyperhomocysteinemia | 3 | 2023 | 28 | 0.320 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 30 | 0.320 |
Why?
|
| Dietary Supplements | 3 | 2020 | 212 | 0.320 |
Why?
|
| Retinal Artery | 2 | 2019 | 10 | 0.320 |
Why?
|
| Middle Aged | 15 | 2024 | 6825 | 0.310 |
Why?
|
| Aspirin | 3 | 2007 | 119 | 0.310 |
Why?
|
| Nitric Oxide Synthase | 7 | 2012 | 34 | 0.310 |
Why?
|
| Glycation End Products, Advanced | 1 | 2008 | 16 | 0.310 |
Why?
|
| Tobacco | 1 | 2009 | 86 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2006 | 187 | 0.300 |
Why?
|
| Transfection | 4 | 2017 | 312 | 0.300 |
Why?
|
| Liposomes | 3 | 2019 | 142 | 0.300 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 47 | 0.300 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 64 | 0.300 |
Why?
|
| Smoke | 1 | 2008 | 33 | 0.300 |
Why?
|
| Neuroprotective Agents | 3 | 2016 | 51 | 0.300 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 70 | 0.290 |
Why?
|
| Models, Immunological | 2 | 2004 | 22 | 0.290 |
Why?
|
| Calcium Signaling | 3 | 2020 | 68 | 0.280 |
Why?
|
| Vasoconstriction | 3 | 2015 | 41 | 0.280 |
Why?
|
| Stroke | 1 | 2010 | 233 | 0.280 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 266 | 0.280 |
Why?
|
| Intracranial Hemorrhages | 3 | 2015 | 30 | 0.280 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2007 | 33 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2019 | 537 | 0.280 |
Why?
|
| Heme Oxygenase-1 | 3 | 2011 | 36 | 0.270 |
Why?
|
| Cyclic AMP | 1 | 2007 | 80 | 0.270 |
Why?
|
| Rats, Inbred Lew | 5 | 2017 | 34 | 0.270 |
Why?
|
| Analysis of Variance | 5 | 2016 | 388 | 0.260 |
Why?
|
| Radiation Injuries | 3 | 2020 | 51 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 802 | 0.260 |
Why?
|
| Atherosclerosis | 3 | 2019 | 91 | 0.260 |
Why?
|
| Sulfonamides | 2 | 2021 | 69 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 22 | 0.250 |
Why?
|
| Exercise Tolerance | 2 | 2017 | 82 | 0.250 |
Why?
|
| Tyrosine | 2 | 2002 | 90 | 0.250 |
Why?
|
| Sex Characteristics | 2 | 2017 | 162 | 0.250 |
Why?
|
| Kidney | 1 | 2007 | 274 | 0.250 |
Why?
|
| Models, Animal | 4 | 2020 | 128 | 0.250 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 3 | 2013 | 16 | 0.240 |
Why?
|
| Exophthalmos | 1 | 2005 | 2 | 0.240 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2005 | 2 | 0.240 |
Why?
|
| Exercise Test | 5 | 2017 | 246 | 0.240 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 194 | 0.240 |
Why?
|
| Risk Factors | 9 | 2020 | 2017 | 0.240 |
Why?
|
| Sleep Deprivation | 2 | 2021 | 27 | 0.240 |
Why?
|
| RNA Interference | 3 | 2010 | 135 | 0.240 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 1927 | 0.240 |
Why?
|
| DNA Repair | 2 | 2017 | 82 | 0.240 |
Why?
|
| Interleukin-6 | 4 | 2011 | 190 | 0.240 |
Why?
|
| Cell Movement | 4 | 2019 | 353 | 0.240 |
Why?
|
| Behavior, Animal | 4 | 2019 | 106 | 0.230 |
Why?
|
| Caveolin 1 | 2 | 2018 | 43 | 0.230 |
Why?
|
| Muscle Contraction | 4 | 2018 | 162 | 0.230 |
Why?
|
| Protein Kinase C | 4 | 2006 | 72 | 0.230 |
Why?
|
| Time Factors | 9 | 2024 | 1564 | 0.230 |
Why?
|
| Fasting | 1 | 2024 | 77 | 0.230 |
Why?
|
| Monocytes | 4 | 2014 | 132 | 0.220 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2013 | 23 | 0.220 |
Why?
|
| Interleukin-17 | 1 | 2004 | 51 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 3 | 2014 | 131 | 0.220 |
Why?
|
| Dietary Fats | 4 | 2011 | 55 | 0.220 |
Why?
|
| Electroretinography | 1 | 2024 | 173 | 0.220 |
Why?
|
| Receptors, Interferon | 1 | 2023 | 12 | 0.220 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2023 | 31 | 0.220 |
Why?
|
| Heart Failure | 4 | 2012 | 232 | 0.210 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 14 | 0.210 |
Why?
|
| Muscle, Skeletal | 5 | 2018 | 578 | 0.210 |
Why?
|
| Retina | 2 | 2024 | 421 | 0.210 |
Why?
|
| Dwarfism, Pituitary | 1 | 2022 | 3 | 0.210 |
Why?
|
| Pericytes | 3 | 2014 | 17 | 0.210 |
Why?
|
| Human Growth Hormone | 1 | 2022 | 14 | 0.210 |
Why?
|
| Models, Biological | 5 | 2012 | 446 | 0.210 |
Why?
|
| Species Specificity | 4 | 2012 | 186 | 0.210 |
Why?
|
| Isoprostanes | 1 | 2002 | 3 | 0.200 |
Why?
|
| Cardiovascular System | 3 | 2013 | 39 | 0.200 |
Why?
|
| Paclitaxel | 1 | 2023 | 183 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 6 | 0.200 |
Why?
|
| Lymphokines | 1 | 2002 | 8 | 0.200 |
Why?
|
| Gray Matter | 1 | 2022 | 23 | 0.200 |
Why?
|
| Simvastatin | 1 | 2002 | 9 | 0.200 |
Why?
|
| Renin-Angiotensin System | 3 | 2007 | 17 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2004 | 213 | 0.200 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 186 | 0.200 |
Why?
|
| Leukoencephalopathies | 1 | 2021 | 5 | 0.190 |
Why?
|
| Stem Cells | 2 | 2014 | 113 | 0.190 |
Why?
|
| Neurons | 5 | 2021 | 273 | 0.190 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 77 | 0.190 |
Why?
|
| Aniline Compounds | 1 | 2021 | 22 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 58 | 0.190 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 54 | 0.190 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 159 | 0.180 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2021 | 8 | 0.180 |
Why?
|
| Intravital Microscopy | 1 | 2021 | 10 | 0.180 |
Why?
|
| Motor Cortex | 1 | 2021 | 45 | 0.180 |
Why?
|
| Superoxide Dismutase | 5 | 2012 | 68 | 0.180 |
Why?
|
| Memory, Short-Term | 4 | 2022 | 62 | 0.180 |
Why?
|
| Capillary Permeability | 1 | 2021 | 38 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 160 | 0.180 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2020 | 22 | 0.180 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2011 | 15 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 509 | 0.180 |
Why?
|
| Motor Activity | 2 | 2019 | 145 | 0.180 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2020 | 6 | 0.180 |
Why?
|
| Disease Progression | 4 | 2023 | 450 | 0.180 |
Why?
|
| Lameness, Animal | 2 | 2017 | 8 | 0.180 |
Why?
|
| Membrane Proteins | 3 | 2020 | 466 | 0.180 |
Why?
|
| Public Health | 1 | 2021 | 84 | 0.180 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 144 | 0.180 |
Why?
|
| Oxidation-Reduction | 5 | 2018 | 352 | 0.170 |
Why?
|
| Kangai-1 Protein | 1 | 2020 | 5 | 0.170 |
Why?
|
| TRPM Cation Channels | 1 | 2020 | 6 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 89 | 0.170 |
Why?
|
| Preventive Medicine | 1 | 2020 | 13 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2002 | 203 | 0.170 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 9 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 57 | 0.170 |
Why?
|
| Phenanthrenes | 1 | 2019 | 10 | 0.170 |
Why?
|
| Lipoproteins, LDL | 2 | 2011 | 36 | 0.170 |
Why?
|
| Choroid | 1 | 2019 | 20 | 0.170 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 128 | 0.170 |
Why?
|
| Paracrine Communication | 2 | 2012 | 16 | 0.170 |
Why?
|
| Betamethasone | 2 | 2010 | 14 | 0.170 |
Why?
|
| TRPC Cation Channels | 3 | 2014 | 33 | 0.160 |
Why?
|
| Lasers | 1 | 2019 | 67 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 44 | 0.160 |
Why?
|
| Cytoprotection | 2 | 2010 | 24 | 0.160 |
Why?
|
| Rodentia | 1 | 2019 | 14 | 0.160 |
Why?
|
| Extracellular Matrix | 2 | 2017 | 110 | 0.160 |
Why?
|
| Retinal Vessels | 1 | 2019 | 71 | 0.160 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2017 | 32 | 0.160 |
Why?
|
| Photic Stimulation | 1 | 2019 | 67 | 0.160 |
Why?
|
| Cerebral Veins | 1 | 2019 | 11 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 33 | 0.160 |
Why?
|
| Myocardium | 3 | 2010 | 171 | 0.160 |
Why?
|
| Visual Perception | 1 | 2019 | 44 | 0.160 |
Why?
|
| Rabbits | 8 | 2011 | 272 | 0.160 |
Why?
|
| Walking | 2 | 2017 | 130 | 0.160 |
Why?
|
| Valsalva Maneuver | 1 | 2018 | 8 | 0.160 |
Why?
|
| Proteostasis | 1 | 2018 | 9 | 0.160 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 64 | 0.160 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2021 | 30 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2019 | 79 | 0.160 |
Why?
|
| Research | 1 | 2019 | 88 | 0.160 |
Why?
|
| Premature Birth | 2 | 2010 | 48 | 0.150 |
Why?
|
| Amyloidogenic Proteins | 1 | 2018 | 7 | 0.150 |
Why?
|
| Vasculitis | 2 | 2011 | 13 | 0.150 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 86 | 0.150 |
Why?
|
| Genomic Instability | 1 | 2018 | 33 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 151 | 0.150 |
Why?
|
| Vascular Resistance | 2 | 2009 | 50 | 0.150 |
Why?
|
| Hand Strength | 2 | 2015 | 33 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 75 | 0.150 |
Why?
|
| Immunohistochemistry | 7 | 2010 | 453 | 0.140 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Mitochondria, Heart | 2 | 2013 | 23 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2023 | 1219 | 0.140 |
Why?
|
| Femoral Artery | 2 | 2010 | 58 | 0.140 |
Why?
|
| Biological Factors | 2 | 2010 | 11 | 0.140 |
Why?
|
| Drug Resistance | 3 | 2007 | 42 | 0.140 |
Why?
|
| Adult | 7 | 2022 | 7389 | 0.130 |
Why?
|
| Heart Diseases | 2 | 2007 | 68 | 0.130 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 7 | 0.130 |
Why?
|
| Ankle Brachial Index | 3 | 2022 | 34 | 0.130 |
Why?
|
| Endothelium | 2 | 2020 | 28 | 0.130 |
Why?
|
| Stress, Mechanical | 2 | 2007 | 102 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2017 | 77 | 0.130 |
Why?
|
| Health Status | 1 | 2017 | 145 | 0.130 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 237 | 0.130 |
Why?
|
| Immunomagnetic Separation | 1 | 2015 | 4 | 0.130 |
Why?
|
| Membrane Fusion | 1 | 2015 | 7 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 108 | 0.130 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2015 | 4 | 0.130 |
Why?
|
| Bivalvia | 2 | 2012 | 18 | 0.130 |
Why?
|
| Muscle Cells | 1 | 2015 | 15 | 0.130 |
Why?
|
| Somatosensory Cortex | 1 | 2015 | 16 | 0.130 |
Why?
|
| Biotin | 1 | 2015 | 25 | 0.130 |
Why?
|
| Phenanthridines | 3 | 2012 | 12 | 0.130 |
Why?
|
| Cell Separation | 1 | 2015 | 55 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2015 | 14 | 0.130 |
Why?
|
| Peptides | 1 | 2018 | 280 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2015 | 36 | 0.130 |
Why?
|
| Oxidoreductases | 2 | 2007 | 56 | 0.120 |
Why?
|
| ADAM17 Protein | 2 | 2006 | 13 | 0.120 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 3 | 0.120 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 13 | 0.120 |
Why?
|
| Pulsatile Flow | 1 | 2015 | 9 | 0.120 |
Why?
|
| Rats, Mutant Strains | 2 | 2014 | 16 | 0.120 |
Why?
|
| Fetal Development | 1 | 2015 | 21 | 0.120 |
Why?
|
| Cell Communication | 1 | 2015 | 66 | 0.120 |
Why?
|
| Interneurons | 1 | 2015 | 24 | 0.120 |
Why?
|
| Pulse Wave Analysis | 3 | 2022 | 29 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2017 | 395 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 245 | 0.120 |
Why?
|
| Spine | 1 | 2015 | 60 | 0.120 |
Why?
|
| Hypoxia | 2 | 2014 | 85 | 0.120 |
Why?
|
| Cerebral Ventricles | 3 | 2010 | 17 | 0.120 |
Why?
|
| ADAM Proteins | 2 | 2006 | 102 | 0.120 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2014 | 7 | 0.120 |
Why?
|
| Endothelin-1 | 1 | 2014 | 10 | 0.120 |
Why?
|
| Bone Density | 1 | 2015 | 99 | 0.120 |
Why?
|
| Neoplasms | 2 | 2017 | 756 | 0.120 |
Why?
|
| Prognosis | 4 | 2020 | 758 | 0.120 |
Why?
|
| Crosses, Genetic | 1 | 2014 | 36 | 0.120 |
Why?
|
| Memory | 4 | 2017 | 71 | 0.120 |
Why?
|
| Biological Evolution | 2 | 2012 | 95 | 0.120 |
Why?
|
| Sucrose | 1 | 2014 | 27 | 0.120 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 38 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2015 | 23 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2015 | 82 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2014 | 49 | 0.110 |
Why?
|
| Cerebrum | 1 | 2013 | 14 | 0.110 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2013 | 4 | 0.110 |
Why?
|
| Cranial Irradiation | 1 | 2013 | 12 | 0.110 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2013 | 5 | 0.110 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 38 | 0.110 |
Why?
|
| Serum Amyloid P-Component | 1 | 2013 | 9 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 80 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2014 | 80 | 0.110 |
Why?
|
| Cell Physiological Phenomena | 1 | 2013 | 7 | 0.110 |
Why?
|
| Vasomotor System | 1 | 2013 | 8 | 0.110 |
Why?
|
| Amidines | 1 | 2013 | 8 | 0.110 |
Why?
|
| Gamma Rays | 1 | 2013 | 28 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2013 | 21 | 0.110 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2010 | 18 | 0.110 |
Why?
|
| NADH, NADPH Oxidoreductases | 2 | 2003 | 11 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 93 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 74 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 254 | 0.100 |
Why?
|
| Protein Carbonylation | 1 | 2012 | 6 | 0.100 |
Why?
|
| Autophagy | 1 | 2013 | 69 | 0.100 |
Why?
|
| Shock, Septic | 1 | 2012 | 38 | 0.100 |
Why?
|
| Enzyme Induction | 2 | 2009 | 27 | 0.100 |
Why?
|
| Pregnancy | 6 | 2015 | 1130 | 0.100 |
Why?
|
| Mitochondria, Muscle | 2 | 2013 | 39 | 0.100 |
Why?
|
| Life Expectancy | 2 | 2012 | 20 | 0.100 |
Why?
|
| Laron Syndrome | 1 | 2012 | 2 | 0.100 |
Why?
|
| Memory Disorders | 3 | 2019 | 47 | 0.100 |
Why?
|
| Haplorhini | 1 | 2012 | 15 | 0.100 |
Why?
|
| Bacteremia | 1 | 2012 | 80 | 0.100 |
Why?
|
| Hominidae | 1 | 2012 | 10 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 31 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 27 | 0.100 |
Why?
|
| Peromyscus | 2 | 2009 | 7 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 114 | 0.100 |
Why?
|
| Calcium | 4 | 2013 | 231 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 408 | 0.100 |
Why?
|
| African Americans | 1 | 2014 | 348 | 0.100 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2011 | 11 | 0.100 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2011 | 12 | 0.090 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 2 | 2010 | 6 | 0.090 |
Why?
|
| Oxidants | 1 | 2011 | 30 | 0.090 |
Why?
|
| Somatomedins | 1 | 2011 | 17 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2012 | 179 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2011 | 111 | 0.090 |
Why?
|
| Acetylcysteine | 1 | 2011 | 24 | 0.090 |
Why?
|
| Interleukins | 1 | 2012 | 108 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 42 | 0.090 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 16 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2010 | 24 | 0.090 |
Why?
|
| Quinazolines | 2 | 2007 | 31 | 0.090 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2010 | 6 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2010 | 2 | 0.090 |
Why?
|
| Glutathione Synthase | 1 | 2010 | 4 | 0.090 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 2 | 0.090 |
Why?
|
| Response Elements | 1 | 2010 | 21 | 0.090 |
Why?
|
| Electron Transport Complex IV | 2 | 2008 | 40 | 0.090 |
Why?
|
| In Vitro Techniques | 4 | 2003 | 239 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 143 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2008 | 117 | 0.090 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2010 | 16 | 0.090 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2007 | 20 | 0.090 |
Why?
|
| Nitric Oxide Donors | 2 | 2007 | 11 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 915 | 0.090 |
Why?
|
| Piperidines | 2 | 2007 | 42 | 0.090 |
Why?
|
| Reference Values | 3 | 2019 | 198 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 93 | 0.090 |
Why?
|
| Genes, Reporter | 1 | 2010 | 88 | 0.090 |
Why?
|
| Cell Line | 1 | 2012 | 671 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 32 | 0.080 |
Why?
|
| Caspase 3 | 3 | 2014 | 56 | 0.080 |
Why?
|
| Resuscitation | 1 | 2010 | 59 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 400 | 0.080 |
Why?
|
| Monocrotaline | 1 | 2009 | 4 | 0.080 |
Why?
|
| Young Adult | 3 | 2022 | 2584 | 0.080 |
Why?
|
| Tumor Necrosis Factors | 1 | 2009 | 14 | 0.080 |
Why?
|
| Random Allocation | 3 | 2017 | 148 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 245 | 0.080 |
Why?
|
| Hyperoxia | 1 | 2010 | 59 | 0.080 |
Why?
|
| Electron Transport | 1 | 2009 | 29 | 0.080 |
Why?
|
| Glutathione | 1 | 2009 | 68 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2017 | 2267 | 0.080 |
Why?
|
| Nitrosation | 1 | 2009 | 4 | 0.080 |
Why?
|
| Depression | 1 | 2011 | 210 | 0.080 |
Why?
|
| Citric Acid Cycle | 1 | 2008 | 14 | 0.080 |
Why?
|
| Genes, ras | 1 | 2008 | 12 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 41 | 0.080 |
Why?
|
| Organ Culture Techniques | 2 | 2006 | 55 | 0.080 |
Why?
|
| Infant, Newborn | 5 | 2011 | 848 | 0.080 |
Why?
|
| Brain Mapping | 2 | 2021 | 199 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 49 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 23 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 22 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2009 | 82 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 161 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2009 | 42 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 58 | 0.080 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2008 | 4 | 0.080 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2008 | 12 | 0.080 |
Why?
|
| Early Diagnosis | 2 | 2020 | 32 | 0.080 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2008 | 9 | 0.080 |
Why?
|
| Smad Proteins | 1 | 2008 | 18 | 0.080 |
Why?
|
| Chiroptera | 1 | 2008 | 6 | 0.080 |
Why?
|
| Potassium Cyanide | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 22 | 0.080 |
Why?
|
| Acetophenones | 4 | 2010 | 9 | 0.080 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2008 | 12 | 0.080 |
Why?
|
| Neuroglia | 1 | 2008 | 30 | 0.080 |
Why?
|
| Energy Intake | 1 | 2008 | 67 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2008 | 68 | 0.080 |
Why?
|
| Carcinoma | 1 | 2008 | 71 | 0.070 |
Why?
|
| Sex Factors | 3 | 2019 | 445 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 80 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 110 | 0.070 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Leukocyte Rolling | 1 | 2007 | 7 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 122 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 61 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 586 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 276 | 0.070 |
Why?
|
| Cannabinoids | 1 | 2007 | 8 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 105 | 0.070 |
Why?
|
| Renal Circulation | 1 | 2007 | 6 | 0.070 |
Why?
|
| Splanchnic Circulation | 1 | 2007 | 7 | 0.070 |
Why?
|
| Proteomics | 1 | 2008 | 177 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 2 | 2017 | 31 | 0.070 |
Why?
|
| Arteritis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Etanercept | 1 | 2007 | 6 | 0.070 |
Why?
|
| Tars | 1 | 2007 | 4 | 0.070 |
Why?
|
| Spatial Memory | 2 | 2018 | 15 | 0.070 |
Why?
|
| Lung | 1 | 2009 | 346 | 0.070 |
Why?
|
| Microglia | 2 | 2019 | 49 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 18 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 188 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 164 | 0.070 |
Why?
|
| Thiocarbamates | 1 | 2006 | 6 | 0.070 |
Why?
|
| Indomethacin | 2 | 2017 | 15 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 2006 | 11 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2017 | 25 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2019 | 860 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2007 | 62 | 0.070 |
Why?
|
| Endothelins | 1 | 2006 | 7 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 26 | 0.070 |
Why?
|
| Gestational Age | 3 | 2015 | 140 | 0.070 |
Why?
|
| Dogs | 2 | 2021 | 504 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 71 | 0.060 |
Why?
|
| Animals, Newborn | 3 | 2011 | 163 | 0.060 |
Why?
|
| Exercise | 1 | 2010 | 451 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 472 | 0.060 |
Why?
|
| Swimming | 2 | 2018 | 31 | 0.060 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2025 | 15 | 0.060 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 115 | 0.060 |
Why?
|
| Protein Binding | 1 | 2007 | 631 | 0.060 |
Why?
|
| Insulin | 3 | 2012 | 309 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2005 | 98 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 2004 | 18 | 0.060 |
Why?
|
| Penicillamine | 1 | 2004 | 9 | 0.060 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 17 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 32 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 63 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 3 | 2014 | 34 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 39 | 0.060 |
Why?
|
| Cystathionine | 1 | 2023 | 6 | 0.060 |
Why?
|
| Methionine | 1 | 2023 | 37 | 0.060 |
Why?
|
| Lateral Ventricles | 2 | 2015 | 8 | 0.060 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 32 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 368 | 0.050 |
Why?
|
| Clathrin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 53 | 0.050 |
Why?
|
| Tetraspanins | 1 | 2023 | 36 | 0.050 |
Why?
|
| Motion Pictures | 1 | 2022 | 3 | 0.050 |
Why?
|
| Interferons | 1 | 2023 | 68 | 0.050 |
Why?
|
| Endocytosis | 1 | 2023 | 81 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 140 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 100 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2002 | 20 | 0.050 |
Why?
|
| 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt | 1 | 2002 | 3 | 0.050 |
Why?
|
| Xanthine Oxidase | 1 | 2002 | 5 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 37 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 83 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 206 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2002 | 30 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 29 | 0.050 |
Why?
|
| Hydrazines | 1 | 2002 | 11 | 0.050 |
Why?
|
| Gap Junctions | 1 | 2002 | 5 | 0.050 |
Why?
|
| Deoxyguanosine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Executive Function | 1 | 2022 | 24 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2002 | 20 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2002 | 51 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 29 | 0.050 |
Why?
|
| Nitrites | 1 | 2002 | 29 | 0.050 |
Why?
|
| Nitrates | 1 | 2002 | 45 | 0.050 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 173 | 0.050 |
Why?
|
| Arginine | 1 | 2002 | 39 | 0.050 |
Why?
|
| DNA | 1 | 2004 | 365 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 6 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2022 | 40 | 0.050 |
Why?
|
| Actins | 2 | 2013 | 93 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2002 | 65 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 11 | 0.050 |
Why?
|
| Osteoporosis | 2 | 2015 | 63 | 0.050 |
Why?
|
| Diet | 1 | 2023 | 222 | 0.050 |
Why?
|
| Ferrets | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cats | 1 | 2021 | 47 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2021 | 15 | 0.050 |
Why?
|
| Plaque, Amyloid | 1 | 2021 | 12 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2021 | 34 | 0.050 |
Why?
|
| Reaction Time | 1 | 2021 | 94 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2015 | 15 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 68 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 55 | 0.050 |
Why?
|
| Glucose Tolerance Test | 2 | 2011 | 57 | 0.050 |
Why?
|
| Neurosciences | 1 | 2020 | 8 | 0.050 |
Why?
|
| Fluorescent Dyes | 3 | 2009 | 87 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 79 | 0.040 |
Why?
|
| Gliosis | 2 | 2010 | 17 | 0.040 |
Why?
|
| Cell Death | 2 | 2010 | 110 | 0.040 |
Why?
|
| Spatial Learning | 1 | 2019 | 6 | 0.040 |
Why?
|
| Rest | 1 | 2020 | 93 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 701 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 73 | 0.040 |
Why?
|
| Angiopoietin-2 | 2 | 2010 | 10 | 0.040 |
Why?
|
| Reversal Learning | 1 | 2018 | 8 | 0.040 |
Why?
|
| Infant, Premature | 2 | 2011 | 133 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 66 | 0.040 |
Why?
|
| Chemokine CCL2 | 2 | 2009 | 43 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2018 | 231 | 0.040 |
Why?
|
| Fetus | 2 | 2008 | 77 | 0.040 |
Why?
|
| Hydroxyl Radical | 1 | 2017 | 7 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2017 | 10 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2017 | 10 | 0.040 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 14 | 0.040 |
Why?
|
| Actigraphy | 1 | 2017 | 22 | 0.040 |
Why?
|
| Community Health Services | 1 | 2017 | 31 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 72 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 93 | 0.030 |
Why?
|
| Onium Compounds | 2 | 2007 | 8 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 7 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 463 | 0.030 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2015 | 4 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Agonists | 1 | 2015 | 4 | 0.030 |
Why?
|
| Vibrissae | 1 | 2015 | 6 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2015 | 19 | 0.030 |
Why?
|
| Nanoconjugates | 1 | 2015 | 18 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2015 | 34 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2015 | 12 | 0.030 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Median Eminence | 1 | 2015 | 2 | 0.030 |
Why?
|
| Postural Balance | 1 | 2015 | 38 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 13 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2015 | 21 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 84 | 0.030 |
Why?
|
| Phosphoproteins | 2 | 2007 | 115 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 9 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2007 | 262 | 0.030 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2014 | 5 | 0.030 |
Why?
|
| Encephalitis | 1 | 2014 | 18 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Brain Edema | 1 | 2014 | 22 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 11 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 2015 | 93 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2014 | 26 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 2014 | 5 | 0.030 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2014 | 7 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 297 | 0.030 |
Why?
|
| Aldehydes | 1 | 2014 | 55 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 67 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2035 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 233 | 0.030 |
Why?
|
| TRPC6 Cation Channel | 1 | 2013 | 6 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Oklahoma | 1 | 2017 | 971 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Secretory Pathway | 1 | 2013 | 6 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 2013 | 24 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 100 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2013 | 13 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2013 | 13 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2012 | 10 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2012 | 20 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2012 | 4 | 0.030 |
Why?
|
| Learning | 1 | 2013 | 92 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 30 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2012 | 23 | 0.030 |
Why?
|
| Seawater | 1 | 2012 | 42 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2012 | 37 | 0.020 |
Why?
|
| Temperature | 1 | 2012 | 207 | 0.020 |
Why?
|
| Hindlimb Suspension | 1 | 2011 | 8 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2011 | 12 | 0.020 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2011 | 11 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 511 | 0.020 |
Why?
|
| Pancreas | 1 | 2011 | 58 | 0.020 |
Why?
|
| Anaerobiosis | 1 | 2010 | 90 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 107 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 202 | 0.020 |
Why?
|
| Microdissection | 1 | 2010 | 14 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP1 Subtype | 1 | 2010 | 2 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 8 | 0.020 |
Why?
|
| Glycerol | 1 | 2010 | 16 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 42 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 10 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2010 | 76 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 2010 | 25 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2010 | 41 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 68 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 40 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 300 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 65 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 59 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 66 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 114 | 0.020 |
Why?
|
| Body Composition | 1 | 2011 | 260 | 0.020 |
Why?
|
| Ethidium | 1 | 2009 | 5 | 0.020 |
Why?
|
| Acridines | 1 | 2009 | 3 | 0.020 |
Why?
|
| Luminescence | 1 | 2009 | 8 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 96 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 332 | 0.020 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Aconitate Hydratase | 1 | 2008 | 4 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2008 | 11 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2008 | 5 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 12 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2008 | 59 | 0.020 |
Why?
|
| Proteins | 1 | 2011 | 244 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 54 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2008 | 11 | 0.020 |
Why?
|
| Food Deprivation | 1 | 2008 | 11 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2008 | 132 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2008 | 6 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 62 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 121 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 21 | 0.020 |
Why?
|
| Fibronectins | 1 | 2008 | 28 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 545 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 86 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 447 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 228 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 24 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 13 | 0.020 |
Why?
|
| Sphingosine | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cadherins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2007 | 37 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2007 | 6 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2007 | 18 | 0.020 |
Why?
|
| Platelet-Rich Plasma | 1 | 2007 | 8 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2007 | 27 | 0.020 |
Why?
|
| Antigens | 1 | 2007 | 66 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2007 | 30 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 2007 | 24 | 0.020 |
Why?
|
| Aborted Fetus | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2007 | 48 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 9 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 60 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 166 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 407 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2008 | 239 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2006 | 73 | 0.020 |
Why?
|
| Collagen | 1 | 2007 | 147 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 151 | 0.020 |
Why?
|
| Benzophenanthridines | 1 | 2004 | 8 | 0.010 |
Why?
|
| Alkaloids | 1 | 2004 | 16 | 0.010 |
Why?
|
| Staurosporine | 1 | 2004 | 10 | 0.010 |
Why?
|
| Captopril | 1 | 2004 | 9 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 33 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2004 | 111 | 0.010 |
Why?
|
| Enzyme Activators | 1 | 2003 | 8 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 63 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 12 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 32 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2002 | 44 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 45 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2002 | 10 | 0.010 |
Why?
|
| Peroxynitrous Acid | 1 | 2002 | 7 | 0.010 |
Why?
|
| Apamin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Nimodipine | 1 | 2002 | 2 | 0.010 |
Why?
|
| Charybdotoxin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Fura-2 | 1 | 2002 | 10 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 75 | 0.010 |
Why?
|
| Physical Conditioning, Animal | 1 | 2002 | 34 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 2002 | 19 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 559 | 0.010 |
Why?
|